Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study aims to determine the effect of metformin along with standard cancer treatment, and its effect on the prognosis of the metastatic breast in non-diabetic patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hager salah el din
• Treatments: Metformin

Criteria

Inclusion Criteria:

• The non-diabetic patients will be included in the study if they meet the following criteria:

1. Confirmed metastatic breast cancer (IV stage) radiologically or by clinical evaluation receiving chemotherapy

2. Age between 18- 70 years.

3. Life expectancy at least 6 months

Exclusion Criteria:

• The patients will be excluded from the study if they have the following criteria:

1. Bad prognosis disease: Criteria defined as the following

• If patient >70 years

• If patient has bad site metastasis (brain)

2. Hypersensitivity for metformin: if happened patient will be treated as following

• Pheniramine Maleate 3 times daily for 7 days and Tablet Dexamethasone 1mg daily in 2 divided doses for 5 days [16].

3. Any condition associated with increased risk of metformin-associated lactic acidosis (e.g., congestive heart failure defined as New York Heart Association {NYHA} Class III or IV functional status; the history of acidosis of any type, severe infections, kidney or liver disease, respiratory disease, seizures .

4. Diabetic patients.